From alcoholism to Parkinson’s, scientists are studying the mechanisms behind the broad clinical potential of weight-loss ...

Sometimes diet and exercise are not enough to help the 100 million Americans with obesity lose weight and prevent health ...

BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the ...

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

BioAge Labs has completed its upsized initial public offering (IPO), raising $198 million after increasing the number of ...

While initially approved for diabetes, GLP-1 drugs are gaining new indications, including the large opportunity in obesity ...

People with type 2 diabetes and obesity who develop kidney disease may benefit more from bariatric surgery than from GLP-1 ...

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United ...

Cantor initiated Amgen (AMGN) coverage with an overweight rating, asserting it was a “big believer” in the biotech company’s ...

Millions of older Americans with obesity could potentially get Medicare's help with the hefty price of a weight-loss ...

California-based biotech BioAge Labs will have its initial public offering of stock. The company is developing Azelaprag, a ...

BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed IPO. Read more here.